E228: The Diagnostic Room: "We're Doing AI" Is Not a Board Answer

<p>In this solo episode of AI For Pharma Growth, Dr Andree Bates explains why “we’re doing AI” is not a credible board answer, and why activity, pilots and steering committees are not the same as strategy.</p><p>Dr Andree breaks down two common answers leadership teams give when asked about AI strategy. </p><p>The episode explores why crowdsourced use cases often become “use case copying” rather than genuine internal innovation. A pain point may be real, and a pilot may work, but that does not mean it is one of the highest-value AI opportunities for the organisation. Without financial modelling, business-unit submissions are only inputs, not prioritisation.</p><p>Dr Andree also outlines four structural conditions that explain why AI investment often fails to realise value: the value prioritisation gap, the decision rights gap, the data ownership conflict, and incentive misalignment. These issues are connected, and if they are diagnosed in the wrong order, the strategy usually fails at the next layer.</p><p>The core message is clear: boards do not need a list of AI activity. They need a strategy they can govern, with clear priorities, financial assumptions, sequencing, ownership and metrics that can be tested over time.</p><p>Topics Covered</p><ul><li><p>Why “we’re doing AI” is not a board answer</p></li><li><p>Activity, demand and value: the difference that matters</p></li><li><p>Why business-unit use cases are not strategy</p></li><li><p>Use case copying and internal innovation theatre</p></li><li><p>The value prioritisation gap</p></li><li><p>Decision rights between pilot and production</p></li><li><p>Data ownership and access conflicts</p></li><li><p>Incentives, adoption and rational resistance</p></li><li><p>What finance needs to see before funding AI</p></li><li><p>What a real board-level AI answer sounds like</p></li></ul><p><br></p><p>Eularis helps pharma and biotech leaders turn AI activity into board-defensible governed strategy and measurable commercial outcomes.<br></p><p>If your CFO asked tomorrow for the projected return of each major AI initiative - by year, across three years, with explicit adoption, operating cost and redeployment assumptions - could you produce an answer that survives scrutiny?<br>And if you could: would you know which of those initiatives most moves the company toward the outcomes it&#39;s exposed on over the next three years? Those are two different questions, and most organisations can&#39;t answer either. A strong init